Istradefylline for OFF Episodes in Parkinson’s Disease: A US Perspective of Common Clinical Scenarios

Istradefylline for OFF Episodes in Parkinson’s Disease: A US Perspective of Common Clinical Scenarios
Degener Neurol Neuromuscul Dis. 2022 Jul 23;12:97-109. doi: 10.2147/DNND.S245197. eCollection 2022.ABSTRACTThe effective management of OFF episodes remains an important unmet need for patients with Parkinson's disease (PD) who develop motor complications with long-term levodopa therapy. Istradefylline is a selective adenosine A2A receptor antagonist for the treatment of patients with PD experiencing OFF episodes while on levodopa/decarboxylase inhibitor. Originally approved in ... read more
Source: PubMedPublished on 2022-08-01By Stuart H Isaacson